Based on a product derived from sea sponge, a new kind of drug has been approved in Europe for treating breast cancer.

People who could not be benefited by previous courses of chemotherapy, will be benefited by Halaven, eribulin mesylate, and it has been stated to be the best possible option for such patients who have locally advanced or metastatic breast cancer and could not derive success out of previous attempts.

Anthracycline and a taxane must have had by patients in previous treatment regimens if they were to receive the latest. In November 2010, the FDA had approved the decision.

By 2.5 months the survival rate is suppose to be increased by eribulin mesylate and this has been stated by the EMBRACE trial, a Phase III study.

UK will be the place where the drug will be launched in the beginning, according to Eisai and then other countries in the northern Europe will receive the drug.

In Aricept, the Japanese pharma had lost patent and this development is bound to be a major relief in gaining a strong market when it comes to hard to treat cancer.

There are trials on for breast cancer being treated by this drug.